DEXCOM INC
DXCMNasdaq · SIC 3841
$76.65
↓ -1.7%Jul 17 close · end-of-day
Price
1Y↓ -8.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$30.2B
Enterprise Value
$29.1B
P/E
32.9
P/S
6.3
P/B
10.2
EV/EBITDA
22.5
PEG
0.9
FCF Yield
4.7%
Dividend Yield
—
Revenue (TTM)
$4.8B
Net Income (TTM)
$930.4M
Free Cash Flow (TTM)
$1.4B
Gross Margin
61.5%
Operating Margin
21.4%
Net Margin
19.3%
ROE
31.5%
ROIC
43.5%
Debt / Equity
—
Net Cash
$1.1B
Return 1Y
-8.9%
Company profile
DexCom, Inc. focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system.
- CEO
- Kevin R. Sayer
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 7,600
- Headquarters
- California
- Website
- dexcom.com
Management & directors
- Brown Michael JonEVP Chief Legal Compliance Off
- Sayer Kevin RExecutive Chair
- Coleman JonEVP, Chief Commercial Officer
- Leach Jacob StevenPresident, CEO, and Director
- Stern SadieEVP Chief People & Culture Off
- Sylvain Jereme MEVP, Chief Financal Officer
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-30
DXCM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.2B↑ +15.0%
Diluted EPS$0.51↑ +88.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.9B | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B |
| Gross profit | $1.3B | $1.7B | $1.9B | $2.3B | $2.4B | $2.8B |
| Operating income | $299.5M | $265.8M | $391.2M | $597.7M | $600.0M | $911.8M |
| Net income | $549.7M | $216.9M | $341.2M | $541.5M | $576.2M | $836.3M |
| Diluted EPS | $1.33 | $0.53 | $0.82 | $1.30 | $1.42 | $2.09 |
| Operating cash flow | $475.6M | $442.5M | $669.5M | $748.5M | $989.5M | $1.4B |
| Free cash flow | $276.6M | $53.3M | $304.7M | $511.9M | $630.7M | $1.1B |
| Gross margin | 66.4% | 68.6% | 64.7% | 63.2% | 60.5% | 60.1% |
| Operating margin | 15.5% | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% |
| Net margin | 28.5% | 8.9% | 11.7% | 14.9% | 14.3% | 17.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $994.2M | $1.1B | $1.0B | $1.2B | $1.2B | $1.3B | $1.2B |
| Gross profit | $626.7M | $593.8M | $655.8M | $589.0M | $688.8M | $731.4M | $792.7M | $750.3M |
| Operating income | $158.0M | $152.0M | $188.9M | $133.7M | $212.6M | $242.5M | $323.0M | $255.3M |
| Net income | $143.5M | $134.6M | $151.7M | $105.4M | $179.8M | $283.8M | $267.3M | $199.5M |
| Diluted EPS | $0.35 | $0.34 | $0.37 | $0.27 | $0.45 | $0.70 | $0.67 | $0.51 |
| Operating cash flow | $279.4M | $199.5M | $301.4M | $183.8M | $303.0M | $659.9M | $294.0M | $525.6M |
| Free cash flow | $213.3M | $88.3M | $176.8M | $96.8M | $208.9M | $579.4M | $192.1M | $449.0M |
| Gross margin | 62.4% | 59.7% | 58.9% | 56.9% | 59.5% | 60.5% | 62.9% | 62.9% |
| Operating margin | 15.7% | 15.3% | 17.0% | 12.9% | 18.4% | 20.1% | 25.6% | 21.4% |
| Net margin | 14.3% | 13.5% | 13.6% | 10.2% | 15.5% | 23.5% | 21.2% | 16.7% |
Company news
Jul 16, 2026
Jul 14, 2026
- 6d agoDXCM Secures Health Canada Authorization for Dexcom G7 15 Day CGMfinance.yahoo.com
- 6d ago1 Mid-Cap Stock to Target This Week and 2 We Find Riskyfinance.yahoo.com
- 6d agoGlobal Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insightsfinance.yahoo.com
Jul 10, 2026
Jul 9, 2026
- 11d agoInvestors’ Confidence in DexCom (DXCM) Rises as Growth Outlook Reassuredfinance.yahoo.com
- 11d agoDexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Timefinance.yahoo.com
- 11d agoHeald Expands Access to AI-Powered Glucose Intelligence for Over-the-Counter CGM Usersfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Brown Michael Jon· EVP Chief Legal Compliance Off | Sale | 1,700 | $74.42 | $126,514.00 | filing |
| 2026-07-06 | SAYER KEVIN R· Executive Chair | Sale | 26,756 | $72.00 | $1.9M | filing |
| 2026-06-15 | FOLETTA MARK G | Sale | 3,801 | $74.10 | $281,650.68 | filing |
| 2026-06-15 | Brown Michael Jon· EVP Chief Legal Compliance Off | Sale | 1,700 | $75.55 | $128,435.00 | filing |
| 2026-06-15 | FOLETTA MARK G | Sale | 199 | $74.82 | $14,888.92 | filing |
| 2026-06-04 | Coleman Jon· EVP, Chief Commercial Officer | Sale | 4,911 | $74.13 | $364,052.43 | filing |
| 2026-06-03 | Coleman Jon· EVP, Chief Commercial Officer | Sale | 4,912 | $73.00 | $358,576.00 | filing |
| 2026-05-28 | Driscoll Rimma | Award | 5,605 | $0.00 | $0.00 | filing |
| 2026-05-28 | Ashley Euan A. | Award | 5,565 | $0.00 | $0.00 | filing |
| 2026-05-28 | Collins Richard Alexander | Award | 5,605 | $0.00 | $0.00 | filing |
| 2026-05-28 | GALA RENEE D | Award | 5,605 | $0.00 | $0.00 | filing |
| 2026-05-28 | ALTMAN STEVEN R | Award | 5,565 | $0.00 | $0.00 | filing |
| 2026-05-28 | Malady Kyle | Award | 5,575 | $0.00 | $0.00 | filing |
| 2026-05-28 | AUGUSTINOS NICHOLAS | Award | 5,575 | $0.00 | $0.00 | filing |
| 2026-05-28 | FOLETTA MARK G | Award | 6,331 | $0.00 | $0.00 | filing |
| 2026-05-28 | Heller Bridgette P | Award | 5,575 | $0.00 | $0.00 | filing |
| 2026-05-28 | Osterloh Albert Frederick IV | Award | 1,630 | $0.00 | $0.00 | filing |
| 2026-05-22 | Coleman Jon· EVP, Chief Commercial Officer | Tax withholding | 7,362 | $71.90 | $529,327.80 | filing |
| 2026-05-22 | Sylvain Jereme M· EVP, Chief Financal Officer | Tax withholding | 1,451 | $71.90 | $104,326.90 | filing |
| 2026-05-22 | Stern Sadie· EVP Chief People & Culture Off | Tax withholding | 1,451 | $71.90 | $104,326.90 | filing |
| 2026-05-22 | Brown Michael Jon· EVP Chief Legal Compliance Off | Tax withholding | 1,451 | $71.90 | $104,326.90 | filing |
| 2026-05-22 | Leach Jacob Steven· President, CEO, and Director | Tax withholding | 1,451 | $71.90 | $104,326.90 | filing |
| 2026-05-21 | SAYER KEVIN R· Executive Chair | Sale | 26,759 | $72.00 | $1.9M | filing |
| 2026-05-15 | Brown Michael Jon· EVP, Chief Legal Officer | Sale | 1,700 | $59.91 | $101,847.00 | filing |
| 2026-05-12 | Heller Bridgette P | Sale | 1,012 | $60.01 | $60,730.12 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.